


Package Leaflet:information for the patient
CellCept 500mg powder for concentrate for solution for infusion
mycophenolate mofetil
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack and other information:
CellCept contains mycophenolate mofetil:
CellCept is used to prevent your body from rejecting a transplanted organ:
CellCept must be used together with other medicines:
WARNING
Mycophenolate causes birth defects and miscarriages. If you are a woman who can become pregnant, you must have a negative pregnancy test before starting treatment and must follow the advice on contraception given by your doctor.
Your doctor will discuss and give you written information, in particular about the effects of mycophenolate on unborn babies. Read this information carefully and follow the instructions.
If you do not understand these instructions completely, please ask your doctor to explain them to you again before taking mycophenolate.
See more information in this section under the headings “Warnings and precautions” and “Pregnancy and breast-feeding”.
Do not take CellCept:
Do not take this medicine if any of the above applies to you. If you are not sure, ask your doctor or nurse before taking CellCept.
Warnings and precautions
Talk to your doctor or nurse before starting treatment with CellCept:
If any of the above applies to you (or you are not sure), ask your doctor or nurse immediately before starting treatment with CellCept.
Effect of sunlight
CellCept reduces your body's defences. For this reason, there is a higher risk of getting skin cancer. Limit the amount of sunlight and UV light you absorb by:
Children
Do not give this medicine to children, as the safety and efficacy of administration to paediatric patients has not been established.
Other medicines and CellCept
Tell your doctor or nurse if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, such as herbal medicines. This is because CellCept may affect the way other medicines work. Also, other medicines may affect the way CellCept works.
In particular, tell your doctor or nurse if you are taking any of the following medicines before starting CellCept:
Vaccines
If you need to have a vaccine (live organism vaccine) during treatment with CellCept, consult your doctor or pharmacist first. Your doctor will advise which vaccines you can have.
Do not donate blood during treatment with CellCept and for at least 6 weeks after stopping treatment. Men should not donate semen during treatment with CellCept and for at least 90 days after stopping treatment.
Contraception in women taking CellCept
If you are a woman who can become pregnant, you must use a reliable method of contraception. This includes:
Talk to your doctor about the most suitable contraceptive method for you. This will depend on your personal situation. It is recommended to use two methods of contraception as this will reduce the risk of unplanned pregnancy. Talk to your doctor as soon as possible if you think your contraceptive method may not have been effective or if you have forgotten to take your contraceptive pill.
You cannot become pregnant if:
Contraception in men taking CellCept
Available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, the risk cannot be completely excluded. As a precaution, it is recommended that you or your female partner use a reliable method of contraception during treatment and for 90 days after stopping CellCept.
If you are planning to have a child, talk to your doctor about the potential risks and alternative treatments.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will discuss with you the potential risks and alternative treatments that can be used to prevent rejection of the transplanted organ if:
If you become pregnant during treatment with mycophenolate, you must inform your doctor immediately. However, keep taking CellCept until you see your doctor.
Pregnancy
Mycophenolate causes a very high frequency of miscarriages (50%) and severe harm to the unborn baby (23-27%). Among the birth defects that have been reported are ear, eye, facial (cleft lip and palate), finger, heart, oesophagus (tube connecting the throat to the stomach), kidney and nervous system defects (such as spina bifida, where the bones of the spine do not develop properly). Your baby may be affected by one or more of these.
If you are a woman who can become pregnant, you must have a negative pregnancy test before starting treatment and must follow the advice on contraception given by your doctor. Your doctor may ask for more than one pregnancy test to make sure you are not pregnant before starting treatment.
Breast-feeding
Do not take CellCept if you are breast-feeding. This is because small amounts of the medicine may pass into breast milk.
Driving and using machines
CellCept has a moderate influence on the ability to drive and use machines. If you feel drowsy, sleepy or confused, talk to your doctor or nurse and do not drive or use tools or machines until you feel better.
CellCept contains polysorbate
This medicine contains 25 mg of polysorbate 80 in each vial. Polysorbates may cause allergic reactions. Talk to your doctor if you have any known allergies.
CellCept contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per vial; this is essentially “sodium-free”.
CellCept is usually given by a doctor or nurse in a hospital. It is given as an intravenous infusion by drip.
Amount to be given
The amount to be given depends on the type of transplant you have. The usual doses are shown below. Treatment will continue until it is necessary to prevent rejection of the transplanted organ.
Kidney transplant
Adults
Liver transplant
Adults
Reconstitution of the medicinal product
The medicine is presented as a powder. This needs to be mixed with glucose before it is given. Your doctor or nurse will reconstitute the medicine and give it to you. They will follow the instructions included in section 7 “Reconstitution of the medicinal product”.
If you are given too much CellCept
If you think you have been given too much medicine, talk to your doctor or nurse immediately.
If you miss a dose of CellCept
If you miss a dose of the medicine, it will be given as soon as possible. Your treatment will then continue at the usual times.
If you stop treatment with CellCept
Do not stop taking CellCept unless your doctor tells you to. If you stop treatment, you may increase the risk of rejection of the transplanted organ.
If you have any further questions on the use of this product, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Talk to your doctor or nurse immediately if you notice any of the following serious side effects, as you may need urgent medical treatment:
Common problems
Some of the most common problems are diarrhoea, reduction in the number of white blood cells or red blood cells in the blood, infection and vomiting. Your doctor will regularly do blood tests to check for any changes in:
Fighting infections
Treatment with CellCept reduces your body's defences. This is to prevent rejection of the transplant. For this reason, your body will not be able to fight infections as effectively as under normal conditions. This means you may get more infections than usual. These include infections affecting the brain, skin, mouth, stomach and gut, lungs and urinary system.
Skin and lymph cancer
As with patients taking this type of medicine (immunosuppressants), a very small number of patients treated with CellCept have developed lymphoid and skin cancer.
General unwanted effects
You may get general unwanted effects that affect your whole body. These include serious allergic reactions (such as anaphylaxis, angioedema), fever, feeling very tired, difficulty sleeping, pain (such as stomach pain, chest pain, joint or muscle pain), headache, flu-like symptoms and swelling.
Other unwanted effects may be:
Skin problemssuch as:
Urinary problemssuch as:
Problems with the digestive system and mouthsuch as:
Nervous system problemssuch as:
Heart and blood vessel problemssuch as:
Lung problemssuch as:
Other problemssuch as:
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
CellCept Composition
The other components are: polysorbate 80, citric acid, hydrochloric acid, sodium chloride (see section 2 "CellCept contains sodium").
Product Appearance and Container Content
Method of Use and Administration Route
CellCept 500 mg powder for concentrate for solution for infusion does not contain antibacterial preservatives; therefore, the reconstitution and dilution of the product must be carried out under aseptic conditions.
The content of each vial of CellCept 500 mg powder for concentrate for solution for infusion must be reconstituted with 14 ml of 5% glucose intravenous infusion solution. A subsequent dilution with 5% glucose intravenous infusion solution is necessary to achieve a final concentration of 6 mg/ml. This means that to prepare a dose of 1 g of mycophenolate mofetil, the content of 2 reconstituted vials (approx. 2 x 15 ml) must be diluted subsequently in 140 ml of 5% glucose intravenous infusion solution. If the infusion solution is not prepared immediately before administration, the start of administration of the infusion solution must be carried out within 3 hours following the reconstitution and dilution of the medication.
Be careful not to let the reconstituted medication get into your eyes.
Be careful not to let the reconstituted medication come into contact with your skin.
CellCept 500 mg powder for concentrate for solution for infusion must be administered as an intravenous infusion. The infusion rate must be controlled to cover a 2-hour administration period.
The intravenous solution of CellCept must never be administered by rapid intravenous injection or bolus.
Marketing Authorization Holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Manufacturer
Roche Pharma AG, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany.
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
|
Czech Republic Roche s.r.o. Tel: +420 - 2 20382111 | Hungary Roche (Hungary) Kft. Tel: +36 – 1 279 4500 |
Denmark Roche Pharmaceuticals A/S Tlf: +45 - 36 39 99 99 | Malta (See Ireland) |
Germany Roche Pharma AG Tel: +49 (0) 7624 140 | Netherlands Roche Nederland B.V. Tel: +31 (0) 348 438050 |
Estonia Roche Eesti OÜ Tel: + 372 - 6 177 380 | Norway Roche Norge AS Tlf: +47 - 22 78 90 00 |
Greece Roche (Hellas) A.E. Τηλ: +30 210 61 66 100 | Austria Roche Austria GmbH Tel: +43 (0) 1 27739 |
Spain Roche Farma S.A. Tel: +34 - 91 324 81 00 | Poland Roche Polska Sp.z o.o. Tel: +48 - 22 345 18 88 |
France Roche Tél: +33 (0)1 47 61 40 00 | Portugal Roche Farmacêutica Química, Lda Tel: +351 - 21 425 70 00 |
Croatia Roche d.o.o. Tel: + 385 1 47 22 333 | Romania Roche România S.R.L. Tel: +40 21 206 47 01 |
Ireland Roche Products (Ireland) Ltd. Tel: +353 (0) 1 469 0700 | Slovenia Roche farmacevtska družba d.o.o. Tel: +386 - 1 360 26 00 |
Iceland Roche Pharmaceuticals A/S c/o Icepharma hf Sími: +354 540 8000 | Slovak Republic Roche Slovensko, s.r.o. Tel: +421 - 2 52638201 |
Italy Roche S.p.A. Tel: +39 - 039 2471 | Finland Roche Oy Puh/Tel: +358 (0) 10 554 500 |
Cyprus Γ.Α.Σταμ?της & Σια Λτδ. Τηλ: +357 - 22 76 62 76 | Sweden Roche AB Tel: +46 (0) 8 726 1200 |
Latvia Roche Latvija SIA Tel: +371 - 6 7039831 | United Kingdom(Northern Ireland) Roche Products (Ireland) Ltd. Tel: +44 (0) 1707 366000 |
Date of the Last Revision of this Prospectus
Detailed information about this medication is available on the European Medicines Agency website http://www.ema.europa.eu
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CELLCEPT 500 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION – subject to medical assessment and local rules.